Outcomes of Obese Coronavirus 2019 Patients Treated with Extra Corporeal Membrane Oxygenation
DOI:
https://doi.org/10.59958/hsf.7383Keywords:
COVID-19, coronavirus, extracorporeal membrane oxygenation, ECMO, obesitAbstract
Background: Veno-venous (VV) extracorporeal membrane oxygenation (ECMO) is used as salvage therapy in severe cases of acute respiratory distress syndrome (ARDS) caused by the coronavirus disease 2019 (COVID-19). Obesity has been linked to worse disease severity and poor outcomes in COVID-19, but there is also a hypothesized obesity survival paradox whereby obese patients fare better in severe illness than their non-obese complement. The effect of obesity on ECMO outcomes in patients with COVID-19 is not well understood. Methods: We performed a retrospective analysis of all patients admitted to our institution who underwent VV ECMO cannulation for COVID-19 in the span of one year. These were separated by body mass index (BMI) with a cutoff of 35 kg/m2 (signifying class 2 obesity or higher) and compared with each other as well as a comparator group of patients with BMI >35 kg/m2 who underwent VV ECMO cannulation for any cause between 2016 and 1 March 2021. Disease severity was categorized using established scoring systems including Apache-II, Charleson-Dayeo, and Murray. Primary endpoints were 30 day mortality, survival to decannulation, and survival to discharge. Results: The study groups were similar in all respects with the exception of BMI. Illness severity, as classified by Charleson-Dayeo, Apache II, and Murray scores not significantly different between groups. The primary outcomes (30-day mortality, survival to decannulation, and survival to discharge) were not significantly different between groups. There was a trend toward more delayed inititation of ECMO therapy in the obese group that was not statistically significant. There was also a trend toward shorter duration of ECMO therapy that did not reach the threshold for statistical significance. Conclusions: There was no significant difference in outcomes between obese and non-obese patients undergoing VV ECMO for COVID-19. Trends toward shorter duration of ECMO and shorter intensive care unit (ICU) and hospital length of stay could represent the “obesity survival paradox” that has been described. Given similar outcomes, obesity should not be a contraindication to ECMO therapy for COVID-19.
References
Keyser A, Philipp A, Zeman F, Lubnow M, Lunz D, Zimmermann M, et al. Percutaneous Cannulation for Extracorporeal Life Support in Severely and Morbidly Obese Patients. Journal of Intensive Care Medicine. 2020; 35: 919–926.
Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009; 374: 1351–1363.
Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Jüni P, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial. JAMA. 2018; 320: 2251–2259.
Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. Journal of Critical Care. 2020; 58: 27–28.
Zeng Y, Cai Z, Xianyu Y, Yang BX, Song T, Yan Q. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Critical Care. 2020; 24: 148.
Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020; 396: 1071–1078.
Ramanathan K, Shekar K, Ling RR, Barbaro RP, Wong SN, Tan CS, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Critical Care. 2021; 25: 211.
Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020; 43: 1392–1398.
Kon ZN, Dahi S, Evans CF, Byrnes KA, Bittle GJ, Wehman B, et al. Class III Obesity is Not a Contraindication to Venovenous Extracorporeal Membrane Oxygenation Support. The Annals of Thoracic Surgery. 2015; 100: 1855–1860.
Cho WH, Oh JY, Yeo HJ, Han J, Kim J, Hong SB, et al. Obesity survival paradox in pneumonia supported with extracorporeal membrane oxygenation: Analysis of the national registry. Journal of Critical Care. 2018; 48: 453–457.
Galvagno SM, Jr, Pelekhaty S, Cornachione CR, Deatrick KB, Mazzeffi MA, Scalea TM, et al. Does Weight Matter? Outcomes in Adult Patients on Venovenous Extracorporeal Membrane Oxygenation When Stratified by Obesity Class. Anesthesia and Analgesia. 2020; 131: 754–761.
Merritt-Genore H, Lyden E, Ryan T, Kwapnoski Z. The effect of patient obesity on extracorporeal membrane oxygenator outcomes and ventilator dependency. Journal of Cardiac Surgery. 2020; 35: 1283–1286.
Kon ZN, Smith DE, Chang SH, Goldenberg RM, Angel LF, Carillo JA, et al. Extracorporeal Membrane Oxygenation Support in Severe COVID-19. The Annals of Thoracic Surgery. 2021; 111: 537–543.
Zaidi SAA, Saleem K. Obesity as a Risk Factor for Failure to Wean from ECMO: A Systematic Review and Meta-Analysis. Canadian Respiratory Journal. 2021; 2021: 9967357.
Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obesity Reviews. 2020; 21: e13128.
Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis. Metabolism: Clinical and Experimental. 2021; 117: 154373.
Nassar M, Nso N, Alfishawy M, Novikov A, Yaghi S, Medina L, et al. Current systematic reviews and meta-analyses of COVID-19. World Journal of Virology. 2021; 10: 182–208.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270–273.
Sanchis-Gomar F, Lavie CJ, Mehra MR, Henry BM, Lippi G. Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide. Mayo Clinic Proceedings. 2020; 95: 1445–1453.
Albashir AAD. The potential impacts of obesity on COVID-19. Clinical Medicine. 2020; 20: e109–e113.
Nie W, Zhang Y, Jee SH, Jung KJ, Li B, Xiu Q. Obesity survival paradox in pneumonia: a meta-analysis. BMC Medicine. 2014; 12: 61.
Zhi G, Xin W, Ying W, Guohong X, Shuying L. "Obesity Paradox" in Acute Respiratory Distress Syndrome: Asystematic Review and Meta-Analysis. PLoS ONE. 2016; 11: e0163677.
Ni YN, Luo J, Yu H, Wang YW, Hu YH, Liu D, et al. Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis. Critical Care. 2017; 21: 36.
Schetz M, De Jong A, Deane AM, Druml W, Hemelaar P, Pelosi P, et al. Obesity in the critically ill: a narrative review. Intensive Care Medicine. 2019; 45: 757–769.
Balik M, Svobodova E, Porizka M, Maly M, Brestovansky P, Volny L, et al. The impact of obesity on the outcome of severe SARS-CoV-2 ARDS in a high volume ECMO centre: ECMO and corticosteroids support the obesity paradox. Journal of Critical Care. 2022; 72: 154162.
